Craig Fraser bought $4,942 of WINT
President and CEO at WINDTREE THERAPEUTICS INC /DE/. 5,431 shares at an average of $0.91, traded Oct 8, 2024, filed Oct 9, 2024.
Score components
- +25RoleCEO
- 0Trade size$5k at market
- +10Relative to holdingsHoldings up 169%
- +18Price context0% above the 52-week low; 96% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -22.0%, 3m -64.1%, 6m -96.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-24-030918, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 8, 2024 | POpen-market purchase Common Stock | +5,431 | $0.91 | $4,942 | 8,638 | Oct 9, 2024 |
Related signals
Other insiders at WINDTREE THERAPEUTICS INC /DE/ and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 54Moderate | WINTbuy WINDTREE THERAPEUTICS INC /DE/ | Craig Fraser President and CEO | $2,650 1,497 shares | +27% | |
| 49Moderate | WINTbuy WINDTREE THERAPEUTICS INC /DE/ | Craig Fraser President and CEO | $2,485 1,315 shares | +31% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.